FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291186567> ?p ?o ?g. }

• W4291186567 endingPage "43" @default.
• W4291186567 startingPage "42.1" @default.
• W4291186567 abstract "Background Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes not only joint pain but also bone destruction resulting in impairment of quality of life. Tumor necrosis factor inhibitors have improved prognosis of patients with rheumatoid arthritis dramatically, especially in combination with methotrexate, however, the optimal dose of the concomitant methotrexate is unclear. Objectives To evaluate the efficacy and safety of adalimumab in combination with reduced dose of methotrexate in patients with early RA with inadequate response to methotrexate. Methods The MIRACLE study was a multinational, randomized, open-label study in patients with RA with inadequate response to methotrexate conducted in Asia. It compared low dose and high dose methotrexate upon starting adalimumab. Methotrexate-naive patients with RA with a disease duration of less than two years started methotrexate at 6 to 8 mg/week and increased it to the maximum tolerable dose by week 12. Patients who have not achieved remission according to simplified disease activity index (SDAI) despite methotrexate ≥ 10 mg/week at week 24 were randomised to the maximum tolerable dose of methotrexate group (10 to 25 mg/week) or the reduced dose group (6 to 8 mg/week) and started to receive subcutaneous adalimumab 40 mg every other week. The primary endpoint was non-inferiority in the achievement of SDAI remission at week 48 in the reduced dose group compared with the maximum tolerable dose group with a non-inferiority margin of -15% based on two-sided 90% confidence interval. ( NCT03505008 ) Results A total of 300 patients were enrolled in the study. Among them, 291 started methotrexate and were included in the analysis. The mean age was 57.7±15.2 years, female was 74.6%, and the mean disease duration from the diagnosis of RA was 21.1±56.2 days. Anti-CCP antibody was positive in 211 (73.0%) and the mean SDAI at study enrollment was 26.5±12.4. At week 24, with the mean dose of methotrexate of 12.6±2.9 mg/week, 108 patients (37.1%) achieved remission according to SDAI and continued MTX monotherapy. 134 patients (46.0%) were randomised and started adalimumab with 68 patients in the maximum tolerable dose group and 66 patients in the reduced dose group. At week 48, the remission achievement rates were 38.4 % and 44.8 %, respectively, with the adjusted risk difference of the reduced dose group to the maximum tolerable dose group of 6.4% (-7.0% to 19.8%, 90% CI), which met the criterion for noninferiority. No significant difference was found in health assessment questionnaire disability index ≤0.5 (59.1% vs 62.0%, respectively, p=0.72) and in radiological remission rates (Δmodified total Sharp score ≤0.5, 66.3% vs 62.0 %, respectively, p=0.59). Adverse drug reactions tended to be more frequent in the maximum tolerable dose group than in the reduced dose group (22.1% vs 9.1%, respectively, p=0.06). Conclusion The MIRACLE randomised study demonstrated that, in patients with inadequate response to methotrexate, the efficacy of adalimumab with reduced dose of concomitant methotrexate was not inferior to that with maximum tolerable dose of methotrexate with better safety profile. Disclosure of Interests Hiroya Tamai Speakers bureau: Eisai, Grant/research support from: Eisai, Kei Ikeda Speakers bureau: AbbVie, Eisai, Eli Lilly, Novartis, Gilead, Asahi-Kasei, Grant/research support from: Mitsubishi-Tanabe, Toshiaki Miyamoto: None declared, Hiroaki Taguchi: None declared, Chang-Fu Kuo: None declared, Kichul Shin: None declared, Shintaro Hirata Speakers bureau: AbbVie, Asahi-Kasei, Astellas, Ayumi, Bristol Myers Squibb, Celgene, Chugai, Eisai, Eli Lilly, Gilead, Glaxo SmithKline, Janssen, Kyorin, Novartis, Pfizer, Sanofi, Tanabe-Mitsubishi, UCB, Paid instructor for: AbbVie, Mitsubishi-Tanabe, Consultant of: AbbVie, Astellas, Bristol Myers Squibb, Eisai, Gilead, Ily Lilly, Grant/research support from: AbbVie, Asahi-Kasei, Eisai, Otsuka, Sanofi, Shionogi, Chugai, Pfizer, Tanabe-Mitsubishi, Eli Lilly, UCB, yutaka okano: None declared, Shinji Sato Speakers bureau: AbbVie, Eisai, Grant/research support from: AbbVie, Eisai, Hidekata Yasuoka Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas, Daiichi-Sankyo, Eisai, Kissei, Takeda, Mitsubishi-Tanabe, Chugai, Novartis, Eli Lilly, Pfizer, Janssen, Sanofi, Teijin, Boehringer-Ingelheim, Bayer, Glaxo Smith Kline, Paid instructor for: AbbVie, Consultant of: AbbVie, Asahi Kasei, Grant/research support from: Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, In Ah Choi Speakers bureau: Abbvie, Eisai, Sung-Hwan Park: None declared, Meng-Yu Weng Paid instructor for: Novartis, Eli Lilly, ChuGai, Abbvie, Consultant of: Abbvie, Masataka Kuwana Speakers bureau: Astellas, Asahi Kasei Pharma, Boehringer-Ingelheim, Chugai, Eisai, Janssen, Mochida, Nippon Shinyaku, Ono Pharmaceuticals, Pfizer, Mitsubishi-Tanabe, Consultant of: Boehringer-Ingelheim, Kissei, Mochida, Grant/research support from: AbbVie, Asahi Kasei Pharma, Boehringer-Ingelheim, Chugai, Eisai, MBL, Nippon Shinyaku, Ono Pharmaceuticals, Mitsubishi-Tanabe, Yun Jong Lee Grant/research support from: Yuhan, Tomonori Ishii Speakers bureau: Chugai, Mitsubishi-Tanabe, Glaxo Smith Kline, Pfizer, Eli Lilly, Janssen, AbbVie, Eisai, Astellas, Jinhyun Kim: None declared, Hideto Kameda Speakers bureau: AbbVie, Pfizer, Consultant of: AbbVie, Grant/research support from: AbbVie, Eisai, Toshihisa Kojima Speakers bureau: AbbVie, Pfizer, Eisai, Grant/research support from: AbbVie, Han Joo Baek: None declared, Ping-Ning Hsu: None declared, Chun-Ming Huang Paid instructor for: Abbvie, Pfizer, Tien-Tsai Cheng Paid instructor for: Abbvie, Grant/research support from: Abbvie, Wan-Yu Sung: None declared, Takehiro Taninaga Shareholder of: Eisai.co.,Ltd., Employee of: Eisai.co.,Ltd., Masahiko Mori Shareholder of: Eisai.co.,Ltd., Employee of: Eisai.co.,Ltd., Hideaki Miyagishi Shareholder of: Eisai.co.,Ltd., Employee of: Eisai.co.,Ltd., Yasunori Sato Speakers bureau: Eisai Co., Ltd. Kowa Company, Ltd., Consultant of: MOCHIDA PHARMACEUTICAL CO., LTD, Tsutomu Takeuchi Speakers bureau: Astellas, AbbVie, Ayumi, Bristol Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Mitsubishi-Tanabe, Nippon-kayaku, Novartis, Pfizer, Sanofi, UCB, Grant/research support from: Asahi Kasei, AbbVie, Ayumi, Boehringer-Ingelheim, Chugai, Eisai, Eli Lilly, Mitsubishi-Tanabe, Sanofi, UCB, Yuko Kaneko Speakers bureau: Asahi Kasei, Astellas, Ayumi, Bristol Myers Squibb, Chugai, Eisai, Elli Lilly, Mitsubishi-Tanabe, Novartis, UCB, Grant/research support from: AbbVie, Chugai, Eisai, Mitsubishi-Tanabe, UCB." @default.
• W4291186567 created "2022-08-13" @default.
• W4291186567 creator A5003413911 @default.
• W4291186567 creator A5011257722 @default.
• W4291186567 creator A5012554706 @default.
• W4291186567 creator A5015483248 @default.
• W4291186567 creator A5017378676 @default.
• W4291186567 creator A5018260972 @default.
• W4291186567 creator A5021607169 @default.
• W4291186567 creator A5025139143 @default.
• W4291186567 creator A5025569123 @default.
• W4291186567 creator A5027786236 @default.
• W4291186567 creator A5032100599 @default.
• W4291186567 creator A5033348080 @default.
• W4291186567 creator A5034004696 @default.
• W4291186567 creator A5035156874 @default.
• W4291186567 creator A5036769318 @default.
• W4291186567 creator A5037136590 @default.
• W4291186567 creator A5039939560 @default.
• W4291186567 creator A5057395696 @default.
• W4291186567 creator A5058753898 @default.
• W4291186567 creator A5072561096 @default.
• W4291186567 creator A5075630907 @default.
• W4291186567 creator A5077238946 @default.
• W4291186567 creator A5078647805 @default.
• W4291186567 creator A5079714073 @default.
• W4291186567 creator A5080972903 @default.
• W4291186567 creator A5081142440 @default.
• W4291186567 creator A5083656099 @default.
• W4291186567 creator A5084593557 @default.
• W4291186567 creator A5087727888 @default.
• W4291186567 creator A5091181205 @default.
• W4291186567 date "2022-05-23" @default.
• W4291186567 modified "2023-09-26" @default.
• W4291186567 title "OP0062 EFFICACY AND SAFETY OF ADALIMUMAB WITH LOW AND HIGH DOSE-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: THE RANDOMISED CONTROLLED MIRACLE STUDY" @default.
• W4291186567 doi "https://doi.org/10.1136/annrheumdis-2022-eular.4" @default.
• W4291186567 hasPublicationYear "2022" @default.
• W4291186567 type Work @default.
• W4291186567 citedByCount "0" @default.
• W4291186567 crossrefType "journal-article" @default.
• W4291186567 hasAuthorship W4291186567A5003413911 @default.
• W4291186567 hasAuthorship W4291186567A5011257722 @default.
• W4291186567 hasAuthorship W4291186567A5012554706 @default.
• W4291186567 hasAuthorship W4291186567A5015483248 @default.
• W4291186567 hasAuthorship W4291186567A5017378676 @default.
• W4291186567 hasAuthorship W4291186567A5018260972 @default.
• W4291186567 hasAuthorship W4291186567A5021607169 @default.
• W4291186567 hasAuthorship W4291186567A5025139143 @default.
• W4291186567 hasAuthorship W4291186567A5025569123 @default.
• W4291186567 hasAuthorship W4291186567A5027786236 @default.
• W4291186567 hasAuthorship W4291186567A5032100599 @default.
• W4291186567 hasAuthorship W4291186567A5033348080 @default.
• W4291186567 hasAuthorship W4291186567A5034004696 @default.
• W4291186567 hasAuthorship W4291186567A5035156874 @default.
• W4291186567 hasAuthorship W4291186567A5036769318 @default.
• W4291186567 hasAuthorship W4291186567A5037136590 @default.
• W4291186567 hasAuthorship W4291186567A5039939560 @default.
• W4291186567 hasAuthorship W4291186567A5057395696 @default.
• W4291186567 hasAuthorship W4291186567A5058753898 @default.
• W4291186567 hasAuthorship W4291186567A5072561096 @default.
• W4291186567 hasAuthorship W4291186567A5075630907 @default.
• W4291186567 hasAuthorship W4291186567A5077238946 @default.
• W4291186567 hasAuthorship W4291186567A5078647805 @default.
• W4291186567 hasAuthorship W4291186567A5079714073 @default.
• W4291186567 hasAuthorship W4291186567A5080972903 @default.
• W4291186567 hasAuthorship W4291186567A5081142440 @default.
• W4291186567 hasAuthorship W4291186567A5083656099 @default.
• W4291186567 hasAuthorship W4291186567A5084593557 @default.
• W4291186567 hasAuthorship W4291186567A5087727888 @default.
• W4291186567 hasAuthorship W4291186567A5091181205 @default.
• W4291186567 hasBestOaLocation W42911865671 @default.
• W4291186567 hasConcept C126322002 @default.
• W4291186567 hasConcept C141071460 @default.
• W4291186567 hasConcept C168563851 @default.
• W4291186567 hasConcept C203092338 @default.
• W4291186567 hasConcept C2777575956 @default.
• W4291186567 hasConcept C2780132546 @default.
• W4291186567 hasConcept C2781059491 @default.
• W4291186567 hasConcept C71924100 @default.
• W4291186567 hasConcept C90924648 @default.
• W4291186567 hasConceptScore W4291186567C126322002 @default.
• W4291186567 hasConceptScore W4291186567C141071460 @default.
• W4291186567 hasConceptScore W4291186567C168563851 @default.
• W4291186567 hasConceptScore W4291186567C203092338 @default.
• W4291186567 hasConceptScore W4291186567C2777575956 @default.
• W4291186567 hasConceptScore W4291186567C2780132546 @default.
• W4291186567 hasConceptScore W4291186567C2781059491 @default.
• W4291186567 hasConceptScore W4291186567C71924100 @default.
• W4291186567 hasConceptScore W4291186567C90924648 @default.
• W4291186567 hasIssue "Suppl 1" @default.
• W4291186567 hasLocation W42911865671 @default.
• W4291186567 hasOpenAccess W4291186567 @default.
• W4291186567 hasPrimaryLocation W42911865671 @default.
• W4291186567 hasRelatedWork W1969918039 @default.
• W4291186567 hasRelatedWork W2006568643 @default.
• W4291186567 hasRelatedWork W2095714646 @default.
• W4291186567 hasRelatedWork W2168751860 @default.
• W4291186567 hasRelatedWork W2793666661 @default.

• next